Recherches "plusieurs pathologies" AcSé Nivolumab Secured Access to Nivolumab for Adult Patients With Selected Rare Cancer Types Paris
Pédiatrie Tumeurs solides AMG 20110261 A Phase 1, Multi-center, Open-label, Dose De-escalation Study to Evaluate the Safety and Efficacy of Talimogene Laherparepvec in Pediatric Subjects With Advanced Non-central Nervous System Tumors That are Amenable to Direct Injection. Paris ISABELLE AERTS
Gynécologie ASCORDIA01 ADNEXMR Scoring System: Impact of an MR Scoring System on Therapeutic Strategy of Pelvic Adnexal Masses Paris, Saint-Cloud CAROLINE MALHAIRE, ROMAN ROUZIER
Phases précoces tumeurs solides CA009-002 (Immuno) A Phase 1/2a Dose Escalation and Cohort Expansion Study for Safety, Tolerability, and Efficacy;of anti-GITR Monoclonal Antibody (BMS-986156) Administered Alone and in Combination;with Nivolumab (BMS-936558, anti PD-1 Monoclonal Antibody) in Advanced Solid Tumors Paris EMANUELA ROMANO
Phases précoces tumeurs solides CA017-003 A Phase 1/2a Study of BMS-986205 Administered in Combination With Nivolumab (Anti-PD-1 Monoclonal Antibody) and in Combination With Both Nivolumab and Ipilimumab (Anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors. Paris CHRISTOPHE LE TOURNEAU
Sein métastatique RH+ COMPLEEMENT-1 An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease. Paris, Saint-Cloud PAUL-HENRI COTTU, FLORENCE LEREBOURS
Phases précoces tumeurs solides CPDR001X2103 Phase Ib, Open-label, Multi-center Study to Characterize the Safety, Tolerability and Pharmacodynamics (PD) of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib). Paris
Pédiatrie Tumeurs solides CPZP034X2203 (VEG116731) A Phase II Study of Pazopanib GW786034, NSC# 737754 in Children, Adolescents and Young Adults With Refractory Solid Tumors. Paris ISABELLE AERTS
Phases précoces tumeurs solides DRIIV-1 (OX2016 -203-01) An open-label, dose-escalation phase I study to assess the safety, pharmacokinetics and pharmacodynamics of AsiDNA, a DNA repair inhibitor administered intravenously in patients with advanced solid tumors. Paris CHRISTOPHE LE TOURNEAU
Phases précoces tumeurs solides M15-819 A Multi-Center, Phase 1, Open-Label, Dose-Escalation Study of ABBV-428, an Immunotherapy in Subjects With Advanced Solid Tumors. Paris CHRISTOPHE LE TOURNEAU